BioCardia, Inc. announced the completion of enrollment and dosing in the low dose cohort of its Phase I/II CardiALLO™ trial, which aims to treat patients with ischemic heart failure of reduced ...
The FDA has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program. This is an expanded access program.
The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd.
Figure 1: Immunomodulatory effects of simulated MSCs. MSCs utilize different molecular mechanisms to suppress (in most cases) or activate immune cells. Orange arrows: inhibition; Green arrows: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback